Olink Proteomics was founded at the University of Uppsala in Sweden in 2016, since then it has built an impressive reputation for itself and supports 1,000 institutes internationally including the top 20 pharma companies (by revenue). Home to a grand repertoire of technologies, the proximity extension assay (PEA) is a standout tool.
Raza Ahmed, Director of Marketing at Olink Proteomics, explained that the PEA uses antibodies with unique DNA oligos to bind target proteins, allowing for accurate detection via qPCR or next-generation sequencing. The dual recognition paired with the antibodies gives the technology remarkable accuracy. From a scaling angle, the PEA can analyse between 5 and 5,400 proteins, meaning it can be used in existing workflows in research labs.
Olink Proteomics caters to a wide range of needs, from target discovery to clinical validation and translation. Ahmed introduced Olink’s extensive portfolio which comprises top-of-the-range products, including Olink Explore HD, Olink Reveal, Target 96, Target 48, and Olink Flex.
The company’s flagship product, Olink Explore HD, measures up to 5,000 products from a single NGS readout. Olink Reveal provides deep coverage of the entire proteome with around 1,000 biomarkers. This offers deep coverage in certain regions like inflammation. Ahmed added that the manual hands-on time is just 2.5 hours and no automation is required.
To address more specific client needs, Olink offers targeted solutions such as Target 96 for specific diseases and Target 48 for cytokines or inflammatory responses. There have been over 2,400 publications on Olink’s technology, many of which illustrate the robustness of the technology across several matrices such as CSF, tissue cell lysates, and extracellular vesicles. Dr. Khashayar Afshari, a Postdoctoral Researcher at the Department of Dermatology at UMass Chan Medical used the technology on skin interstitial fluid to profile different inflammatory skin conditions.
Olink Proteomics was selected by the UK Biobank for the world's largest human proteomic study. The project will use Olink’s Explore HD to measure and analyse 5,400 proteins across 600,000 samples to transform the study of disease. This impressive achievement is a testament to the quality and consistency of Olink Proteomics' services and its ability to serve the diverse needs of the life sciences community. Hopefully, this study will generate more interesting discoveries and insights into certain diseases.
